The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2021 | Horizon scan: multiple myeloma treatment landscape
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses the changing treatment landscape of multiple myeloma. Prof. Cerchione outlines novel therapies including monoclonal antibodies, proteasome inhibitors, chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engager therapies (BiTEs). In particular, Prof. Cerchione highlights promising real-world data on monoclonal antibody therapies in the front-line setting and lenalidomide maintenance therapy for multiple myeloma. This interview took place during the 2021 European Myeloma Network (EMN) congress.
